Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 121.9% in April

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 7,100 shares, a growth of 121.9% from the March 31st total of 3,200 shares. Based on an average daily volume of 7,300 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Up 0.3 %

NASDAQ CALT traded up $0.05 during trading hours on Friday, hitting $19.50. The company’s stock had a trading volume of 3,791 shares, compared to its average volume of 7,766. The stock has a fifty day moving average of $20.86 and a 200 day moving average of $20.61. Calliditas Therapeutics AB has a twelve month low of $15.25 and a twelve month high of $29.30. The firm has a market capitalization of $580.92 million, a P/E ratio of -11.89 and a beta of 1.50. The company has a quick ratio of 3.08, a current ratio of 3.13 and a debt-to-equity ratio of 2.89.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its earnings results on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. The firm had revenue of $42.45 million during the quarter, compared to the consensus estimate of $36.24 million. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. Equities research analysts forecast that Calliditas Therapeutics AB will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.